Aktuellt
SENASTE
Redeye has a positive view of Orexo after the Q1 report, but we see a challenge to stabilising the Zubsolv revenues. At the same time, there is significant potential in Orexo's AmorphOX technology and the OX124 spray.
LÄS MER
